Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NEW JCM GROUP
300157
5
Shenzhen S-king Intelligent Equipment
688328
US OptionsDetailed Quotes
GILD250502C106000
- 0.96
- +0.26+37.14%
15min DelayTrading Apr 28 11:58 ET
1.00High0.46Low
0.46Open0.70Pre Close22 Volume162 Open Interest106.00Strike Price1.59KTurnover31.07%IV1.70%PremiumMay 2, 2025Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.96Extrinsic Value100Contract SizeAmericanOptions Type0.4131Delta0.1124Gamma101.61Leverage Ratio-0.1797Theta0.0048Rho41.97Eff Leverage0.0434Vega
Gilead Sciences Newsroom
HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Gilead Sciences (GILD)
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Gilead Sciences: Strong Market Position and Positive Long-Term Outlook Justify Buy Rating
Express News | Gilead : HSBC Raises Target Price to $93 From $82
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
Gilead Sciences First Quarter 2025 Earnings: Misses Expectations
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $135
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Gilead Sciences' Earnings Call: Growth Amid Challenges
Gilead Sciences To Go Ex-Dividend On June 13th, 2025 With 0.79 USD Dividend Per Share
Top Gap Ups and Downs on Friday: GOOGL, TMUS, GILD and More
Why Gilead Sciences Stock Slipped Today
Alphabet, Intel, T-Mobile, Pinterest, Meta, Palantir, Gilead: Biggest Stock Movers
How Is The Market Feeling About Gilead Sciences?
Gilead Delivers Lackluster Q1 Revenue on Trodelvy Miss, Oppenheimer Says
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
